GFAP and chronic kidney disease: The primary objective of this study was to investigate whether plasma levels of NfL, p-Tau231, and GFAP are elevated in patients with CKD stages 3 and 4, i.e. in a group of patients with marked reductions in GFR in which these biomarkers have not been comprehensively examined.